Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Organon & Co.OGN · Entity 4115 | Gen. Counsel & Corp. Secy. | March 31, 2026 | April 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Organon & Co.
Report date March 31, 2026 · Filed April 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 92,639.163 |
Ending reported balance
After 2026-03-31 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2026-03-31 · Exercise / conversion · Acquired 6,201 · Balance 85,602.163 Row 2 · 2026-03-31 · Tax withholding · Disposed 1,767 · Balance 83,835.163 F1: The price is the closing market price of Organon & Co. ("Organon") common stock on Monday, March 30, 2026, as required by the plan under which the Restricted Stock Units ("RSU") were granted. Row 3 · 2026-03-31 · Exercise / conversion · Acquired 12,312 · Balance 96,147.163 Row 4 · 2026-03-31 · Tax withholding · Disposed 3,508 · Balance 92,639.163 F1: The price is the closing market price of Organon & Co. ("Organon") common stock on Monday, March 30, 2026, as required by the plan under which the Restricted Stock Units ("RSU") were granted. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 183,639 |
Reported balance
After 2026-03-31 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-03-31 · Grant · Acquired 183,639 · Balance 183,639 F2: On March 31, 2026, the Reporting Person was granted 183,639 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-03-31 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-03-31 · Exercise / conversion · Disposed 6,201 · Balance 0 F3: Each RSU represents a contingent right to receive one share of Organon common stock. F4: On March 31, 2023, the Reporting Person was granted 18,600 RSUs. Two-thirds of such RSUs previously vested, and the remaining one-third vested on March 31, 2026. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 24,625 |
Reported balance
After 2026-03-31 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-03-31 · Exercise / conversion · Disposed 12,312 · Balance 24,625 F3: Each RSU represents a contingent right to receive one share of Organon common stock. F5: On March 31, 2025, the Reporting Person was granted 36,937 RSUs. One-third of such RSUs vested on March 31, 2026, with the remaining two-thirds to vest on March 31, 2027 and March 31, 2028. |
Filing footnotes · ownership attribution and instrument terms
F1: The price is the closing market price of Organon & Co. ("Organon") common stock on Monday, March 30, 2026, as required by the plan under which the Restricted Stock Units ("RSU") were granted.
F2: On March 31, 2026, the Reporting Person was granted 183,639 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029.
F3: Each RSU represents a contingent right to receive one share of Organon common stock.
F4: On March 31, 2023, the Reporting Person was granted 18,600 RSUs. Two-thirds of such RSUs previously vested, and the remaining one-third vested on March 31, 2026.
F5: On March 31, 2025, the Reporting Person was granted 36,937 RSUs. One-third of such RSUs vested on March 31, 2026, with the remaining two-thirds to vest on March 31, 2027 and March 31, 2028.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 31, 2026 Filed Apr 2, 2026 16:09 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionRestricted Stock Units · Derivative | 12,312 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-023146 · wk-form4_1775160581.xml · derivative · entry 7 Weaver Kirke · CIK 0001959622 · Gen. Counsel & Corp. Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,625 Underlying: Common Stock · 12,312 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Organon common stock. F5 · derivative.exercise_date: On March 31, 2025, the Reporting Person was granted 36,937 RSUs. One-third of such RSUs vested on March 31, 2026, with the remaining two-thirds to vest on March 31, 2027 and March 31, 2028. F5 · derivative.expiration_date: On March 31, 2025, the Reporting Person was granted 36,937 RSUs. One-third of such RSUs vested on March 31, 2026, with the remaining two-thirds to vest on March 31, 2027 and March 31, 2028. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 16:09 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionRestricted Stock Units · Derivative | 6,201 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-023146 · wk-form4_1775160581.xml · derivative · entry 6 Weaver Kirke · CIK 0001959622 · Gen. Counsel & Corp. Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,201 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Organon common stock. F4 · derivative.exercise_date: On March 31, 2023, the Reporting Person was granted 18,600 RSUs. Two-thirds of such RSUs previously vested, and the remaining one-third vested on March 31, 2026. F4 · derivative.expiration_date: On March 31, 2023, the Reporting Person was granted 18,600 RSUs. Two-thirds of such RSUs previously vested, and the remaining one-third vested on March 31, 2026. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 16:09 UTC | Organon & Co. OGN · Entity 4115 | GrantRestricted Stock Units · Derivative | 183,639 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-023146 · wk-form4_1775160581.xml · derivative · entry 5 Weaver Kirke · CIK 0001959622 · Gen. Counsel & Corp. Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 183,639 Underlying: Common Stock · 183,639 shares Expires not disclosed F2 · derivative.exercise_price: On March 31, 2026, the Reporting Person was granted 183,639 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029. F2 · derivative.exercise_date: On March 31, 2026, the Reporting Person was granted 183,639 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029. F2 · derivative.expiration_date: On March 31, 2026, the Reporting Person was granted 183,639 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 16:09 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 3,508 | $5.70 | $19,995.60 |
DisclosureSEC source: 0001628280-26-023146 · wk-form4_1775160581.xml · nonDerivative · entry 4 Weaver Kirke · CIK 0001959622 · Gen. Counsel & Corp. Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,639.163 F1 · price: The price is the closing market price of Organon & Co. ("Organon") common stock on Monday, March 30, 2026, as required by the plan under which the Restricted Stock Units ("RSU") were granted. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 16:09 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionCommon Stock | 12,312 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-023146 · wk-form4_1775160581.xml · nonDerivative · entry 3 Weaver Kirke · CIK 0001959622 · Gen. Counsel & Corp. Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,147.163 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 16:09 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 1,767 | $5.70 | $10,071.90 |
DisclosureSEC source: 0001628280-26-023146 · wk-form4_1775160581.xml · nonDerivative · entry 2 Weaver Kirke · CIK 0001959622 · Gen. Counsel & Corp. Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,835.163 F1 · price: The price is the closing market price of Organon & Co. ("Organon") common stock on Monday, March 30, 2026, as required by the plan under which the Restricted Stock Units ("RSU") were granted. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 16:09 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionCommon Stock | 6,201 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-023146 · wk-form4_1775160581.xml · nonDerivative · entry 1 Weaver Kirke · CIK 0001959622 · Gen. Counsel & Corp. Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,602.163 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 29, 2026 Filed Mar 31, 2026 16:12 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionRestricted Stock Units · Derivative | 7,757 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-022410 · wk-form4_1774987975.xml · derivative · entry 3 Weaver Kirke · CIK 0001959622 · Gen. Counsel & Corp. Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,757 Underlying: Common Stock · 7,757 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Organon common stock. F3 · derivative.exercise_date: These RSUs vest and are distributed as shares of Organon common stock in three equal installments on March 29, 2025, March 29, 2026, and March 29, 2027. F3 · derivative.expiration_date: These RSUs vest and are distributed as shares of Organon common stock in three equal installments on March 29, 2025, March 29, 2026, and March 29, 2027. Read SEC document |
| March 29, 2026 Filed Mar 31, 2026 16:12 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 2,210 | $5.84 | $12,906.40 |
DisclosureSEC source: 0001628280-26-022410 · wk-form4_1774987975.xml · nonDerivative · entry 2 Weaver Kirke · CIK 0001959622 · Gen. Counsel & Corp. Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,401.163 F1 · price: This price is the closing market price of Organon & Co. ("Organon") common stock on Friday, March 27, 2026, as required by the plan under which the Restricted Stock Units ("RSU") were awarded. Read SEC document |
| March 29, 2026 Filed Mar 31, 2026 16:12 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionCommon Stock | 7,757 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-022410 · wk-form4_1774987975.xml · nonDerivative · entry 1 Weaver Kirke · CIK 0001959622 · Gen. Counsel & Corp. Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,611.163 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 18:58 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 1,763 | $7.23 | $12,746.49 |
DisclosureSEC source: 0001628280-26-014222 · wk-form4_1772582299.xml · nonDerivative · entry 4 Weaver Kirke · CIK 0001959622 · Gen. Counsel & Corp. Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,854.163 F3 · balance_after: Includes the addition of 1,832.163 shares of Common Stock acquired from dividend equivalents not previously required to be reported. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 18:58 UTC | Organon & Co. OGN · Entity 4115 | GrantCommon Stock | 6,186 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-014222 · wk-form4_1772582299.xml · nonDerivative · entry 3 Weaver Kirke · CIK 0001959622 · Gen. Counsel & Corp. Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,785 F2 · shares: Represents the shares of Common Stock released to cover the dividend equivalents earned on the PSUs released above. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 18:58 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 6,815 | $7.17 | $48,863.55 |
DisclosureSEC source: 0001628280-26-014222 · wk-form4_1772582299.xml · nonDerivative · entry 2 Weaver Kirke · CIK 0001959622 · Gen. Counsel & Corp. Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,599 Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 18:58 UTC | Organon & Co. OGN · Entity 4115 | GrantCommon Stock | 21,925 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-014222 · wk-form4_1772582299.xml · nonDerivative · entry 1 Weaver Kirke · CIK 0001959622 · Gen. Counsel & Corp. Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,414 F1 · shares: Represents shares of Organon & Co. common stock ("Common Stock") for performance share units ("PSUs") granted to the reporting person on August 11, 2023 under the Organon & Co. 2021 Incentive Stock Plan. The performance-vesting restrictions with respect to these shares were released upon certification of performance goal attainment by the Talent Committee of Organon's Board of Directors. Read SEC document |
| May 06, 2025 Filed May 7, 2025 12:12 UTC | Organon & Co. OGN · Entity 4115 | PurchaseCommon Stock | 8,045 | $9.21 | $74,054.23 |
DisclosureSEC source: 0001821825-25-000031 · wk-form4_1746634336.xml · nonDerivative · entry 1 Weaver Kirke · CIK 0001959622 · Gen. Counsel & Corp. Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,489 Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 17:39 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionRestricted Stock Units · Derivative | 4,294 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-25-000010 · wk-form4_1743629980.xml · derivative · entry 14 Weaver Kirke · CIK 0001959622 · Gen. Counsel & Corp. Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,294 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU converts into one share of Organon common stock. F8 · derivative.exercise_date: On March 31, 2022, RSUs were awarded and on March 31, 2025, the final third of these RSUs vested. F8 · derivative.expiration_date: On March 31, 2022, RSUs were awarded and on March 31, 2025, the final third of these RSUs vested. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 17:39 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionRestricted Stock Units · Derivative | 3,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-25-000010 · wk-form4_1743629980.xml · derivative · entry 13 Weaver Kirke · CIK 0001959622 · Gen. Counsel & Corp. Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,125 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU converts into one share of Organon common stock. F7 · derivative.exercise_date: On November 7, 2022, RSUs were awarded and on March 31, 2025, the final third of these RSUs vested. F7 · derivative.expiration_date: On November 7, 2022, RSUs were awarded and on March 31, 2025, the final third of these RSUs vested. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 17:39 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionRestricted Stock Units · Derivative | 6,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-25-000010 · wk-form4_1743629980.xml · derivative · entry 12 Weaver Kirke · CIK 0001959622 · Gen. Counsel & Corp. Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,200 Underlying: Common Stock · 6,200 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU converts into one share of Organon common stock. F6 · derivative.exercise_date: On March 31, 2023, RSUs were awarded and on March 31, 2025, one-third of these RSUs vested with the remaining RSUs to vest on March 31, 2026. F6 · derivative.expiration_date: On March 31, 2023, RSUs were awarded and on March 31, 2025, one-third of these RSUs vested with the remaining RSUs to vest on March 31, 2026. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 17:39 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionRestricted Stock Units · Derivative | 7,757 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-25-000010 · wk-form4_1743629980.xml · derivative · entry 11 Weaver Kirke · CIK 0001959622 · Gen. Counsel & Corp. Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,514 Underlying: Common Stock · 7,757 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU converts into one share of Organon common stock. F5 · derivative.exercise_date: On March 29, 2024, RSUs were granted and on March 29, 2025, one-third of these RSUs vested, with the remaining RSUs to vest on March 29, 2026, and March 29, 2027. Since the first anniversary of the date of grant was on Saturday, March 29, 2025, the vesting occurred on Monday, March 31, 2025, the next business day. F5 · derivative.expiration_date: On March 29, 2024, RSUs were granted and on March 29, 2025, one-third of these RSUs vested, with the remaining RSUs to vest on March 29, 2026, and March 29, 2027. Since the first anniversary of the date of grant was on Saturday, March 29, 2025, the vesting occurred on Monday, March 31, 2025, the next business day. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 17:39 UTC | Organon & Co. OGN · Entity 4115 | GrantRestricted Stock Units · Derivative | 36,937 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-25-000010 · wk-form4_1743629980.xml · derivative · entry 10 Weaver Kirke · CIK 0001959622 · Gen. Counsel & Corp. Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,937 Underlying: Common Stock · 36,937 shares Expires not disclosed F3 · derivative.exercise_price: Each RSU converts into one share of Organon common stock. F4 · derivative.exercise_date: The Reporting Person was granted RSUs, which represent a contingent right to receive one share of Organon common stock for each RSU. On March 31, 2025, RSUs were granted and will vest in three equal installments on each of March 31, 2026, March 31, 2027, and March 31, 2028. F4 · derivative.expiration_date: The Reporting Person was granted RSUs, which represent a contingent right to receive one share of Organon common stock for each RSU. On March 31, 2025, RSUs were granted and will vest in three equal installments on each of March 31, 2026, March 31, 2027, and March 31, 2028. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 17:39 UTC | Organon & Co. OGN · Entity 4115 | GrantStock Option (right to buy) · Derivative | 181,518 | $0.00 Strike: $14.89 | $0.00 |
DisclosureSEC source: 0001821825-25-000010 · wk-form4_1743629980.xml · derivative · entry 9 Weaver Kirke · CIK 0001959622 · Gen. Counsel & Corp. Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 181,518 Underlying: Common Stock · 181,518 shares Expires not disclosed F2 · derivative.exercise_date: The Reporting Person was granted stock options, which vest and become exercisable in three equal installments on March 31, 2026, March 31, 2027, and March 31, 2028. F2 · derivative.expiration_date: The Reporting Person was granted stock options, which vest and become exercisable in three equal installments on March 31, 2026, March 31, 2027, and March 31, 2028. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 17:39 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 1,224 | $14.51 | $17,760.24 |
DisclosureSEC source: 0001821825-25-000010 · wk-form4_1743629980.xml · nonDerivative · entry 8 Weaver Kirke · CIK 0001959622 · Gen. Counsel & Corp. Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,444 F1 · price: This price is the closing market price of Organon & Co. ("Organon") common stock on Friday, March 28, 2025, as required by the plan under which the Restricted Stock Units ("RSU") were awarded. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 17:39 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionCommon Stock | 4,294 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-25-000010 · wk-form4_1743629980.xml · nonDerivative · entry 7 Weaver Kirke · CIK 0001959622 · Gen. Counsel & Corp. Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,668 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 17:39 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 891 | $14.51 | $12,928.41 |
DisclosureSEC source: 0001821825-25-000010 · wk-form4_1743629980.xml · nonDerivative · entry 6 Weaver Kirke · CIK 0001959622 · Gen. Counsel & Corp. Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,374 F1 · price: This price is the closing market price of Organon & Co. ("Organon") common stock on Friday, March 28, 2025, as required by the plan under which the Restricted Stock Units ("RSU") were awarded. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 17:39 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionCommon Stock | 3,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-25-000010 · wk-form4_1743629980.xml · nonDerivative · entry 5 Weaver Kirke · CIK 0001959622 · Gen. Counsel & Corp. Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,265 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 17:39 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 1,767 | $14.51 | $25,639.17 |
DisclosureSEC source: 0001821825-25-000010 · wk-form4_1743629980.xml · nonDerivative · entry 4 Weaver Kirke · CIK 0001959622 · Gen. Counsel & Corp. Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,140 F1 · price: This price is the closing market price of Organon & Co. ("Organon") common stock on Friday, March 28, 2025, as required by the plan under which the Restricted Stock Units ("RSU") were awarded. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 17:39 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionCommon Stock | 6,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-25-000010 · wk-form4_1743629980.xml · nonDerivative · entry 3 Weaver Kirke · CIK 0001959622 · Gen. Counsel & Corp. Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,907 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 17:39 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 2,210 | $14.51 | $32,067.10 |
DisclosureSEC source: 0001821825-25-000010 · wk-form4_1743629980.xml · nonDerivative · entry 2 Weaver Kirke · CIK 0001959622 · Gen. Counsel & Corp. Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,707 F1 · price: This price is the closing market price of Organon & Co. ("Organon") common stock on Friday, March 28, 2025, as required by the plan under which the Restricted Stock Units ("RSU") were awarded. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 17:39 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionCommon Stock | 7,757 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-25-000010 · wk-form4_1743629980.xml · nonDerivative · entry 1 Weaver Kirke · CIK 0001959622 · Gen. Counsel & Corp. Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,917 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 04, 2024 Filed May 7, 2024 16:06 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionRestricted Stock Units · Derivative | 1,248 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-24-000061 · wk-form4_1715112359.xml · derivative · entry 3 Weaver Kirke · CIK 0001959622 · Gen. Counsel & Corp. Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,248 shares Expires 2023-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. F2 · derivative.exercise_date: On each of May 4, 2022, May 4, 2023 and May 4, 2024, one-third of the RSUs vested. F2 · derivative.expiration_date: On each of May 4, 2022, May 4, 2023 and May 4, 2024, one-third of the RSUs vested. Read SEC document |
| May 04, 2024 Filed May 7, 2024 16:06 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 356 | $19.61 | $6,981.16 |
DisclosureSEC source: 0001821825-24-000061 · wk-form4_1715112359.xml · nonDerivative · entry 2 Weaver Kirke · CIK 0001959622 · Gen. Counsel & Corp. Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,160 Read SEC document |
| May 04, 2024 Filed May 7, 2024 16:06 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionCommon Stock | 1,248 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-24-000061 · wk-form4_1715112359.xml · nonDerivative · entry 1 Weaver Kirke · CIK 0001959622 · Gen. Counsel & Corp. Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,516 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2024 Filed Apr 3, 2024 18:40 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionRestricted Stock Units · Derivative | 6,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-24-000044 · wk-form4_1712184027.xml · derivative · entry 9 Weaver Kirke · CIK 0001959622 · Gen. Counsel & Corp. Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,400 Underlying: Common Stock · 6,200 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit converts into one share of Organon & Co. ("Organon") common stock. F4 · derivative.exercise_date: The Reporting Person was granted RSUs on March 31, 2023. On March 31, 2024, one-third of the RSUs vested with the remaining RSUs to vest in two equal installments on March 31, 2025 and March 31, 2026. F4 · derivative.expiration_date: The Reporting Person was granted RSUs on March 31, 2023. On March 31, 2024, one-third of the RSUs vested with the remaining RSUs to vest in two equal installments on March 31, 2025 and March 31, 2026. Read SEC document |
| March 31, 2024 Filed Apr 3, 2024 18:40 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionRestricted Stock Units · Derivative | 3,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-24-000044 · wk-form4_1712184027.xml · derivative · entry 8 Weaver Kirke · CIK 0001959622 · Gen. Counsel & Corp. Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,125 Underlying: Common Stock · 3,125 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit converts into one share of Organon & Co. ("Organon") common stock. F3 · derivative.exercise_price: The Reporting Person was granted RSUs on November 7, 2022, which represent a contingent right to receive one share of Organon common stock for each RSU. On each of March 31, 2023, and March 31, 2024, one-third of the RSUs vested, with the remaining RSUs to vest on March 31, 2025. F2 · derivative.exercise_date: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon common stock for each RSU. On each of March 31, 2023, and March 31, 2024, one-third of the RSUs vested, with the remaining RSUs to vest on March 31, 2025. F2 · derivative.expiration_date: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon common stock for each RSU. On each of March 31, 2023, and March 31, 2024, one-third of the RSUs vested, with the remaining RSUs to vest on March 31, 2025. Read SEC document |
| March 31, 2024 Filed Apr 3, 2024 18:40 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionRestricted Stock Units · Derivative | 4,294 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-24-000044 · wk-form4_1712184027.xml · derivative · entry 7 Weaver Kirke · CIK 0001959622 · Gen. Counsel & Corp. Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,294 Underlying: Common Stock · 4,294 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit converts into one share of Organon & Co. ("Organon") common stock. F2 · derivative.exercise_date: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon common stock for each RSU. On each of March 31, 2023, and March 31, 2024, one-third of the RSUs vested, with the remaining RSUs to vest on March 31, 2025. F2 · derivative.expiration_date: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon common stock for each RSU. On each of March 31, 2023, and March 31, 2024, one-third of the RSUs vested, with the remaining RSUs to vest on March 31, 2025. Read SEC document |
| March 31, 2024 Filed Apr 3, 2024 18:40 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 891 | $18.80 | $16,750.80 |
DisclosureSEC source: 0001821825-24-000044 · wk-form4_1712184027.xml · nonDerivative · entry 6 Weaver Kirke · CIK 0001959622 · Gen. Counsel & Corp. Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,268 Read SEC document |
| March 31, 2024 Filed Apr 3, 2024 18:40 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionCommon Stock | 3,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-24-000044 · wk-form4_1712184027.xml · nonDerivative · entry 5 Weaver Kirke · CIK 0001959622 · Gen. Counsel & Corp. Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,159 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2024 Filed Apr 3, 2024 18:40 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 1,767 | $18.80 | $33,219.60 |
DisclosureSEC source: 0001821825-24-000044 · wk-form4_1712184027.xml · nonDerivative · entry 4 Weaver Kirke · CIK 0001959622 · Gen. Counsel & Corp. Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,034 Read SEC document |
| March 31, 2024 Filed Apr 3, 2024 18:40 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionCommon Stock | 6,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-24-000044 · wk-form4_1712184027.xml · nonDerivative · entry 3 Weaver Kirke · CIK 0001959622 · Gen. Counsel & Corp. Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,801 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2024 Filed Apr 3, 2024 18:40 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 1,224 | $18.80 | $23,011.20 |
DisclosureSEC source: 0001821825-24-000044 · wk-form4_1712184027.xml · nonDerivative · entry 2 Weaver Kirke · CIK 0001959622 · Gen. Counsel & Corp. Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,601 Read SEC document |
| March 31, 2024 Filed Apr 3, 2024 18:40 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionCommon Stock | 4,294 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-24-000044 · wk-form4_1712184027.xml · nonDerivative · entry 1 Weaver Kirke · CIK 0001959622 · Gen. Counsel & Corp. Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,825 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 29, 2024 Filed Apr 2, 2024 16:21 UTC | Organon & Co. OGN · Entity 4115 | GrantStock Option (right to buy) · Derivative | 95,315 | $0.00 Strike: $18.80 | $0.00 |
DisclosureSEC source: 0001821825-24-000022 · wk-form4_1712089307.xml · derivative · entry 2 Weaver Kirke · CIK 0001959622 · Gen. Counsel & Corp. Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,315 Underlying: Common Stock · 95,315 shares Expires 2027-03-29 F3 · derivative.exercise_date: The Reporting Person was granted stock options, which vest and become exercisable in three equal installments on March 29, 2025, March 29, 2026, and March 29, 2027. Read SEC document |
| March 29, 2024 Filed Apr 2, 2024 16:21 UTC | Organon & Co. OGN · Entity 4115 | GrantRestricted Stock Units · Derivative | 23,271 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-24-000022 · wk-form4_1712089307.xml · derivative · entry 1 Weaver Kirke · CIK 0001959622 · Gen. Counsel & Corp. Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,271 Underlying: Common Stock · 23,271 shares Expires 2027-03-29 F1 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. F2 · derivative.exercise_date: These RSUs vest and are distributed as shares of Organon common stock in three equal installments on March 29, 2025, March 29, 2026, and March 29, 2027. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 16:24 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionRestricted Stock Units · Derivative | 4,957 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-24-000013 · wk-form4_1709328287.xml · derivative · entry 3 Weaver Kirke · CIK 0001959622 · Gen. Counsel & Corp. Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,957 shares Expires 2023-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit converts into one share of Organon & Co. common stock. F2 · date: As previously reported, these Restricted Stock Units vested on December 31, 2023, and shares of Organon & Co. common stock were distributed to the Reporting Person on February 28, 2024. F2 · derivative.exercise_date: As previously reported, these Restricted Stock Units vested on December 31, 2023, and shares of Organon & Co. common stock were distributed to the Reporting Person on February 28, 2024. F2 · derivative.expiration_date: As previously reported, these Restricted Stock Units vested on December 31, 2023, and shares of Organon & Co. common stock were distributed to the Reporting Person on February 28, 2024. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 16:24 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 1,607 | $18.04 | $28,990.28 |
DisclosureSEC source: 0001821825-24-000013 · wk-form4_1709328287.xml · nonDerivative · entry 2 Weaver Kirke · CIK 0001959622 · Gen. Counsel & Corp. Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,531 Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 16:24 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionCommon Stock | 4,957 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001821825-24-000013 · wk-form4_1709328287.xml · nonDerivative · entry 1 Weaver Kirke · CIK 0001959622 · Gen. Counsel & Corp. Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,138 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit converts into one share of Organon & Co. common stock. Read SEC document |
| February 22, 2024 Filed Feb 23, 2024 11:46 UTC | Organon & Co. OGN · Entity 4115 | PurchaseCommon Stock | 2,720 | $18.36 | $49,938.93 |
DisclosureSEC source: 0001821825-24-000002 · wk-form4_1708706810.xml · nonDerivative · entry 1 Weaver Kirke · CIK 0001959622 · Gen. Counsel & Corp. Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,181 Read SEC document |
| May 04, 2023 Filed May 8, 2023 18:46 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionRestricted Stock Units · Derivative | 1,246 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-028106 · doc4.xml · derivative · entry 3 Weaver Kirke · CIK 0001959622 · Gen. Counsel & Corp. Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,248 Underlying: Common Stock · 1,246 shares Expires 2023-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On each of May 4, 2022 and May 4, 2023, one-third of the RSUs vested, with the remaining RSUs to vest on May 4, 2024. F1 · derivative.exercise_date: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On each of May 4, 2022 and May 4, 2023, one-third of the RSUs vested, with the remaining RSUs to vest on May 4, 2024. F1 · derivative.expiration_date: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On each of May 4, 2022 and May 4, 2023, one-third of the RSUs vested, with the remaining RSUs to vest on May 4, 2024. Read SEC document |
| May 04, 2023 Filed May 8, 2023 18:46 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 355 | $24.24 | $8,605.20 |
DisclosureSEC source: 0001209191-23-028106 · doc4.xml · nonDerivative · entry 2 Weaver Kirke · CIK 0001959622 · Gen. Counsel & Corp. Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,461 Read SEC document |
| May 04, 2023 Filed May 8, 2023 18:46 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionCommon Stock | 1,246 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-028106 · doc4.xml · nonDerivative · entry 1 Weaver Kirke · CIK 0001959622 · Gen. Counsel & Corp. Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,816 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On each of May 4, 2022 and May 4, 2023, one-third of the RSUs vested, with the remaining RSUs to vest on May 4, 2024. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.